Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 3
1998 1
1999 1
2002 2
2003 3
2004 2
2005 1
2008 3
2009 1
2010 3
2011 2
2012 3
2013 5
2014 6
2015 5
2016 5
2017 2
2018 1
2020 4
2022 3
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.
Albracht SP. Albracht SP. Cancer Treat Res Commun. 2022;31:100537. doi: 10.1016/j.ctarc.2022.100537. Epub 2022 Feb 18. Cancer Treat Res Commun. 2022. PMID: 35217488 Free article. Review.
GcMAF (Group-specific component Macrophage-Activating Factor) is a mammalian protein with an incredible potency to directly activate macrophages. ...From Yamamoto's data it can be calculated that GcMAF is a near-stoichiometric acti …
GcMAF (Group-specific component Macrophage-Activating Factor) is a mammalian protein with an incredible p …
Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.
Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N. Inui T, et al. Anticancer Res. 2014 Aug;34(8):4589-93. Anticancer Res. 2014. PMID: 25075104
Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. ...This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SD …
Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. ...This case …
Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Yamamoto N, et al. Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. doi: 10.1007/s00262-007-0431-z. Cancer Immunol Immunother. 2008. PMID: 18058096 Retracted.
Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). ...Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase genera …
Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-acti …
Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N, Suyama H, Yamamoto N. Yamamoto N, et al. Transl Oncol. 2008 Jul;1(2):65-72. doi: 10.1593/tlo.08106. Transl Oncol. 2008. PMID: 18633461 Free PMC article.
Serum Gc protein (known as vitamin D(3)-binding protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of prostate cancer patients was los …
Serum Gc protein (known as vitamin D(3)-binding protein) is the precursor for the principal macrophage …
Clinical experience of integrative cancer immunotherapy with GcMAF.
Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N. Inui T, et al. Anticancer Res. 2013 Jul;33(7):2917-9. Anticancer Res. 2013. PMID: 23780980
However, in the clinical setting, the results of cancer immunotherapy are mixed. We therefore contend that cancer immunotherapy should be customized to each patient individually based on their immune status and propose an integrative immunotherapy approach with seco …
However, in the clinical setting, the results of cancer immunotherapy are mixed. We therefore contend that cancer immunotherap …
Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K, Mette M, Inui T, Endo Y, Hori H. Kuchiike D, et al. Anticancer Res. 2013 Jul;33(7):2881-5. Anticancer Res. 2013. PMID: 23780974
BACKGROUND: The group-specific component protein-derived macrophage-activating factor (GcMAF) has various biological activities, such as macrophage activation and antitumor activity. ...CONCLUSION: We demonstrated that GcMAF-contai …
BACKGROUND: The group-specific component protein-derived macrophage-activating factor (GcMAF) has various …
GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.
Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. Thyer L, et al. Oncoimmunology. 2013 Aug 1;2(8):e25769. doi: 10.4161/onci.25769. Epub 2013 Jul 29. Oncoimmunology. 2013. PMID: 24179708 Free PMC article.
The administration of GC protein-derived macrophage-activating factor (GcMAF) to cancer patients with elevated levels of nagalase has been associated with a decrease of serum nagalase activity and with significant clinical benefits. Here, …
The administration of GC protein-derived macrophage-activating factor (GcMAF) to cancer patients w …
Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Yamamoto N, et al. Int J Cancer. 2008 Jan 15;122(2):461-7. doi: 10.1002/ijc.23107. Int J Cancer. 2008. PMID: 17935130 Free article. Retracted.
Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). ...Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated p …
Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating …
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Inui T, Amitani H, Kubo K, Kuchiike D, Uto Y, Nishikata T, Mette M. Inui T, et al. Anticancer Res. 2016 Jul;36(7):3767-70. Anticancer Res. 2016. PMID: 27354652
BACKGROUND/AIM: Macrophage activating factor (MAF)-based immunotherapy has a wide application for use in treating many diseases via macrophage activation. ...CONCLUSION: This case report suggests a new concept of cancer treatment using local des …
BACKGROUND/AIM: Macrophage activating factor (MAF)-based immunotherapy has a wide application for use in treating many …
56 results